Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2020, , 311 - 318, 27.10.2020

İdris Buğra Çerik , Ferhat Dindaş , Emin Koyun İbrahim Gül

https://doi.org/10.7197/cmj.vi.782892

Öz

Kaynakça

  • Referans1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-64 DOI: 10.1093/eurheartj/ehv318.
  • Referans2. Strobbe A, Adriaenssens T, Bennett J, Dubois C, Desmet W, McCutcheon K, Van Cleemput J, Sinnaeve PR. Etiology and Long-Term Outcome of Patients Undergoing Pericardiocentesis. J Am Heart Assoc. 2017;6(12) DOI: 10.1161/jaha.117.007598.
  • Referans3. Louw VJ, Reuter H, Smedema JP, Katjitae I, Burgess LJ, Doubell AF. Clinical experience with pericardiocentesis and extended drainage in a population with a high prevalence of HIV. Neth Heart J. 2002;10(10):399-406.
  • Referans4. Saltzman AJ, Paz YE, Rene AG, Green P, Hassanin A, Argenziano MG, Rabbani L, Dangas G. Comparison of surgical pericardial drainage with percutaneous catheter drainage for pericardial effusion. J Invasive Cardiol. 2012;24(11):590-3.
  • Referans5. Vayre F, Lardoux H, Pezzano M, Bourdarias JP, Dubourg O. Subxiphoid pericardiocentesis guided by contrast two-dimensional echocardiography in cardiac tamponade: experience of 110 consecutive patients. Eur J Echocardiogr. 2000;1(1):66-71 DOI: 10.1053/euje.1999.0003.
  • Referans6. Sethi A, Singbal Y, Kodumuri V, Prasad V. Inpatient mortality and its predictors after pericardiocentesis: An analysis from the Nationwide Inpatient Sample 2009-2013. J Interv Cardiol. 2018;31(6):815-25 DOI: 10.1111/joic.12563.
  • Referans7. Kim SH, Kwak MH, Park S, Kim HJ, Lee HS, Kim MS, Lee JM, Zo JI, Ro JS, Lee JS. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat. 2010;42(4):210-6 DOI: 10.4143/crt.2010.42.4.210.
  • Referans8. Jama GM, Scarci M, Bowden J, Marciniak SJ. Palliative treatment for symptomatic malignant pericardial effusion†. Interact Cardiovasc Thorac Surg. 2014;19(6):1019-26 DOI: 10.1093/icvts/ivu267.
  • Referans9. Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH, Hayes SN. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc. 2000;75(3):248-53 DOI: 10.4065/75.3.248.
  • Referans10. Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34(16):1186-97 DOI: 10.1093/eurheartj/ehs372.
  • Referans11. Fröhlich GM, Keller P, Schmid F, Wolfrum M, Osranek M, Falk C, Noll G, Enseleit F, Reinthaler M, Meier P, Lüscher TF, Ruschitzka F, Tanner FC. Haemodynamically irrelevant pericardial effusion is associated with increased mortality in patients with chronic heart failure. Eur Heart J. 2013;34(19):1414-23 DOI: 10.1093/eurheartj/eht006.
  • Referans12. Gad MM, Elgendy IY, Mahmoud AN, Elbadawi A, Tanavin T, Denktas A, Jimenez E, Kapadia SR, Jneid H. Temporal trends, outcomes, and predictors of mortality after pericardiocentesis in the United States. Catheter Cardiovasc Interv. 2020;95(3):375-86 DOI: 10.1002/ccd.28588.
  • Referans13. Burazor I, Imazio M, Markel G, Adler Y. Malignant pericardial effusion. Cardiology. 2013;124(4):224-32 DOI: 10.1159/000348559.
  • Referans14. Meyers DG, Meyers RE, Prendergast TW. The usefulness of diagnostic tests on pericardial fluid. Chest. 1997;111(5):1213-21 DOI: 10.1378/chest.111.5.1213.
  • Referans15. Minai K, Komukai K, Arase S, Nagoshi T, Matsuo S, Ogawa K, Kayama Y, Inada K, Tanigawa S, Takemoto T, Sekiyama H, Date T, Ogawa T, Taniguchi I, Yoshimura M. Cardiac tamponade as an independent condition affecting the relationship between the plasma B-type natriuretic peptide levels and cardiac function. Heart Vessels. 2013;28(4):510-3 DOI: 10.1007/s00380-012-0278-x.
  • Referans16. Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, Shimasaki Y, Ogawa H, Kugiyama K, Saito Y, Nakao K, Yasue H. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000;86(9):1036-40, a11 DOI: 10.1016/s0002-9149(00)01147-4.
  • Referans17. Brereton WF, Sherlock P, Cameron DJ. PERICARDIAL EFFUSION. MARKED SERUM TRANSAMINASE ELEVATIONS: A REPORT OF FOUR CASES. Arch Intern Med. 1965;115:311-4 DOI: 10.1001/archinte.1965.03860150055010.
  • Referans18. Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, Wan Q, He R, Wang Z. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis. 2017;259:75-82 DOI: 10.1016/j.atherosclerosis.2017.02.003.
  • Referans19. Zhang X, Guo M, Fan J, Lv Z, Huang Q, Han J, Wu F, Hu G, Xu J, Jin Y. Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis. Cancer Biomark. 2016;16(3):415-23 DOI: 10.3233/cbm-160580.
  • Referans20. Deng T, Zhang J, Meng Y, Zhou Y, Li W. Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer. Medicine (Baltimore). 2018;97(38):e12524 DOI: 10.1097/md.0000000000012524.
  • Referans21. Said NM. Three gold indicators for breast cancer prognosis: a case-control study with ROC analysis for novel ratios related to CBC with (ALP and LDH). Mol Biol Rep. 2019;46(2):2013-27 DOI: 10.1007/s11033-019-04650-9.

Cancer prevalence, inpatient mortality and its predictors after pericardiocentesis

Yıl 2020, , 311 - 318, 27.10.2020

İdris Buğra Çerik , Ferhat Dindaş , Emin Koyun İbrahim Gül

https://doi.org/10.7197/cmj.vi.782892

Öz

Objective: Pericardiocentesis is a percutaneous drainage procedure performed in cardiac tamponade or a moderate-large pericardial effusion that does not respond to medical treatment. The prognosis varies according to the etiology of pericardial effusion, and the parameters that can determine the prognosis are unknown. 
In this study, we aimed to find predictors that can determine inpatient mortality in patients who underwent pericardiocentesis and to determine cancer etiology. 
Method: Ninety-one patients who underwent pericardiocentesis due to moderate-large pericardial effusion or pericardial tamponade were evaluated retrospectively. Baseline characteristics of the patients, their cancer diagnosis before and after pericardiocentesis, pericardial effusion cytology, echocardiographic parameters and laboratory parameters in the baseline evaluation were evaluated. The group with inpatient death (n = 14) and the surviving group (n = 77) were compared with each other. 
Results: There was no significant difference between baseline demographic characteristics and echocardiographic parameters when the patients with inpatient mortality and survivors were compared; only patients diagnosed with cancer (p <0.001) and patients with malignant cytology (p = 0.041) were statistically significantly higher in the group with inpatient mortality. When patients with inpatient mortality and survivors were compared in terms of laboratory parameters, aspartate aminotransferase (AST) [55 (27-455), 26 (19-45); p = 0.007, respectively], lactate dehydrogenase (LDH) [527 (438-944), 282 (225-381); p <0.001, respectively], C-reactive protein (CRP) [120.5 (19.8-140.7), 36.5 (8.26-86.15); p = 0.016, respectively], NTproBNP [8964 (7780-9432), 1310 (351-4556); p = 0.049] values were significantly higher in the inpatient mortality group than in the surviving group. The presence of cancer (p = 0.001), AST (p = 0.008), alanine aminotransferase (ALT) (p = 0.013), LDH (p = 0.015), CRP (p = 0.046) parameters were detected to be predictors that can be used to predict inpatient mortality in the univariate logistic regression analysis conducted to determine the predictors that could indicate inpatient mortality. 
Conclusions: Inpatient mortality is high in patients that were detected to have underlying malignancy and pericardial involvement after pericardiocentesis. In the initial evaluation of these patients, simple laboratory tests such as AST, ALT, NTproBNP, LDH, CRP can give an idea about the short-term prognosis of the disease.

Anahtar Kelimeler

pericardiocentesis mortality cancer

Kaynakça

  • Referans1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-64 DOI: 10.1093/eurheartj/ehv318.
  • Referans2. Strobbe A, Adriaenssens T, Bennett J, Dubois C, Desmet W, McCutcheon K, Van Cleemput J, Sinnaeve PR. Etiology and Long-Term Outcome of Patients Undergoing Pericardiocentesis. J Am Heart Assoc. 2017;6(12) DOI: 10.1161/jaha.117.007598.
  • Referans3. Louw VJ, Reuter H, Smedema JP, Katjitae I, Burgess LJ, Doubell AF. Clinical experience with pericardiocentesis and extended drainage in a population with a high prevalence of HIV. Neth Heart J. 2002;10(10):399-406.
  • Referans4. Saltzman AJ, Paz YE, Rene AG, Green P, Hassanin A, Argenziano MG, Rabbani L, Dangas G. Comparison of surgical pericardial drainage with percutaneous catheter drainage for pericardial effusion. J Invasive Cardiol. 2012;24(11):590-3.
  • Referans5. Vayre F, Lardoux H, Pezzano M, Bourdarias JP, Dubourg O. Subxiphoid pericardiocentesis guided by contrast two-dimensional echocardiography in cardiac tamponade: experience of 110 consecutive patients. Eur J Echocardiogr. 2000;1(1):66-71 DOI: 10.1053/euje.1999.0003.
  • Referans6. Sethi A, Singbal Y, Kodumuri V, Prasad V. Inpatient mortality and its predictors after pericardiocentesis: An analysis from the Nationwide Inpatient Sample 2009-2013. J Interv Cardiol. 2018;31(6):815-25 DOI: 10.1111/joic.12563.
  • Referans7. Kim SH, Kwak MH, Park S, Kim HJ, Lee HS, Kim MS, Lee JM, Zo JI, Ro JS, Lee JS. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat. 2010;42(4):210-6 DOI: 10.4143/crt.2010.42.4.210.
  • Referans8. Jama GM, Scarci M, Bowden J, Marciniak SJ. Palliative treatment for symptomatic malignant pericardial effusion†. Interact Cardiovasc Thorac Surg. 2014;19(6):1019-26 DOI: 10.1093/icvts/ivu267.
  • Referans9. Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH, Hayes SN. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc. 2000;75(3):248-53 DOI: 10.4065/75.3.248.
  • Referans10. Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34(16):1186-97 DOI: 10.1093/eurheartj/ehs372.
  • Referans11. Fröhlich GM, Keller P, Schmid F, Wolfrum M, Osranek M, Falk C, Noll G, Enseleit F, Reinthaler M, Meier P, Lüscher TF, Ruschitzka F, Tanner FC. Haemodynamically irrelevant pericardial effusion is associated with increased mortality in patients with chronic heart failure. Eur Heart J. 2013;34(19):1414-23 DOI: 10.1093/eurheartj/eht006.
  • Referans12. Gad MM, Elgendy IY, Mahmoud AN, Elbadawi A, Tanavin T, Denktas A, Jimenez E, Kapadia SR, Jneid H. Temporal trends, outcomes, and predictors of mortality after pericardiocentesis in the United States. Catheter Cardiovasc Interv. 2020;95(3):375-86 DOI: 10.1002/ccd.28588.
  • Referans13. Burazor I, Imazio M, Markel G, Adler Y. Malignant pericardial effusion. Cardiology. 2013;124(4):224-32 DOI: 10.1159/000348559.
  • Referans14. Meyers DG, Meyers RE, Prendergast TW. The usefulness of diagnostic tests on pericardial fluid. Chest. 1997;111(5):1213-21 DOI: 10.1378/chest.111.5.1213.
  • Referans15. Minai K, Komukai K, Arase S, Nagoshi T, Matsuo S, Ogawa K, Kayama Y, Inada K, Tanigawa S, Takemoto T, Sekiyama H, Date T, Ogawa T, Taniguchi I, Yoshimura M. Cardiac tamponade as an independent condition affecting the relationship between the plasma B-type natriuretic peptide levels and cardiac function. Heart Vessels. 2013;28(4):510-3 DOI: 10.1007/s00380-012-0278-x.
  • Referans16. Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, Shimasaki Y, Ogawa H, Kugiyama K, Saito Y, Nakao K, Yasue H. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000;86(9):1036-40, a11 DOI: 10.1016/s0002-9149(00)01147-4.
  • Referans17. Brereton WF, Sherlock P, Cameron DJ. PERICARDIAL EFFUSION. MARKED SERUM TRANSAMINASE ELEVATIONS: A REPORT OF FOUR CASES. Arch Intern Med. 1965;115:311-4 DOI: 10.1001/archinte.1965.03860150055010.
  • Referans18. Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, Wan Q, He R, Wang Z. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis. 2017;259:75-82 DOI: 10.1016/j.atherosclerosis.2017.02.003.
  • Referans19. Zhang X, Guo M, Fan J, Lv Z, Huang Q, Han J, Wu F, Hu G, Xu J, Jin Y. Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis. Cancer Biomark. 2016;16(3):415-23 DOI: 10.3233/cbm-160580.
  • Referans20. Deng T, Zhang J, Meng Y, Zhou Y, Li W. Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer. Medicine (Baltimore). 2018;97(38):e12524 DOI: 10.1097/md.0000000000012524.
  • Referans21. Said NM. Three gold indicators for breast cancer prognosis: a case-control study with ROC analysis for novel ratios related to CBC with (ALP and LDH). Mol Biol Rep. 2019;46(2):2013-27 DOI: 10.1007/s11033-019-04650-9.
Toplam 21 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Medical Science Research Makaleler
Yazarlar

İdris Buğra Çerik 0000-0003-1419-3950

Ferhat Dindaş 0000-0003-0053-9594

Emin Koyun 0000-0001-9823-1613

İbrahim Gül 0000-0003-1007-0961

Yayımlanma Tarihi 27 Ekim 2020
Kabul Tarihi 18 Eylül 2020
Yayımlandığı Sayı Yıl 2020

Kaynak Göster

AMA Çerik İB, Dindaş F, Koyun E, Gül İ. Cancer prevalence, inpatient mortality and its predictors after pericardiocentesis. CMJ. Ekim 2020;42(3):311-318. doi:10.7197/cmj.vi.782892